CK7可作为预测子宫颈CIN1进展的免疫标志物——来自四价HPV疫苗实验人群的回顾性研究

发布时间：2018-05-14 06:27

本文选题：子宫颈癌 + HPV疫苗　；参考：《临床与实验病理学杂志》2017年09期

【摘要】：正子宫颈高级别上皮内病变(CIN2-3)是起源于鳞柱交界(SCJ)的独特细胞群。CK7作为鳞柱交界细胞群的免疫组化标志物,被应用于低级别上皮内病变(即CIN1)的诊断。本实验将一小部分可能进展为CIN2-3的病例分离出来,其余大多数CIN1病例不需要进一步干预治疗。作者回顾性分析子宫颈CIN1组织中CK7的表达情况,材料来自HPV疫苗实验中使用安慰剂的人群。免疫组化染色判读:阴性、斑驳阳性、分层阳性(即上-下)及全层阳性。
[Abstract]:CIN2-3) is a unique cell group originated from SCJs. CK7 is used as an immunocytochemical marker of SCJs and is used in the diagnosis of low grade intraepithelial lesions (CIN1). In this study, a small number of cases that may progress to CIN2-3 were isolated, and most of the remaining CIN1 cases did not require further intervention. The authors retrospectively analyzed the expression of CK7 in cervical CIN1 tissues from people who used placebo in HPV vaccine trials. Immunohistochemical staining: negative, mottled positive, stratified positive (i.e. upper-lower) and the whole layer positive.
【作者单位】：解放军第180医院病理科;解放军福州总医院病理科;
【分类号】：R737.33

【相似文献】